Plain-English translation of NCT02453542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is testing new blood tests that can better measure whether bypass medications—like FEIBA or recombinant activated factor VII—are working to stop bleeding in people with hemophilia who have developed antibodies against standard treatments. Currently, doctors have trouble knowing if these medications are actually helping because traditional blood tests don't work well in these situations. This study hopes to find better ways to monitor treatment so patients stay safer and their care is more effective.
Some people with hemophilia develop antibodies (the body's immune defense) against the standard clotting factor medicines, making those treatments stop working. These patients need different medications to control bleeding, but doctors can't easily tell if the new treatment is actually working because standard blood tests don't measure it properly. This study exists to find new blood tests that can accurately track whether the medication is doing its job.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital to have blood samples drawn at specific times over a two-year period—at the start of the study and before and after you receive your bleeding disorder medication. The actual treatment you receive (type, dose, and how often) will be decided by your regular doctor, not the study. Your participation mainly involves allowing the researchers to collect these blood samples and test them with new methods to see how well your medication is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Sweden